Multiple Sclerosis Therapeutic Market – By Drug Class (Immunosuppressants, Immunostimulants, Immunomodulators), Route of Administration (Oral, Injectable [Intramuscular, Intravenous]), Distribution Channel (Hospital, Retail, Online) – Global Forecast, 2024 – 2032

Multiple Sclerosis Therapeutic Market Size

Multiple Sclerosis Therapeutic Market size was valued at around USD 25.5 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032. Multiple sclerosis therapeutics encompasses various treatments and medications used in the management of multiple sclerosis, a chronic autoimmune disease that affects the central nervous system (CNS). Multiple sclerosis leads to the degradation of the myelin sheath, the protective covering of nerve fibers, resulting in disrupted communication between the brain and the rest of the body.
 

The rising incidence of multiple sclerosis is a significant driver of market growth. For instance, according to the World Health Organization (WHO), multiple sclerosis affects over 2.8 million people worldwide, with a higher prevalence among young adults and females. This underscores the increasing demand for effective multiple sclerosis therapeutics, driving research and development efforts to introduce innovative treatments that address the growing patient population.
 

Additionally, advancements in drug development, a growing focus on personalized medicine, and a rising geriatric population are key factors driving market growth.
 

Multiple Sclerosis Therapeutic Market Trends

Advancements in drug development for multiple sclerosis therapeutics have led to significant improvements in disease management. Over the past decade, emerging therapies have demonstrated superior efficacy and addressed the varied needs of patients. These developments are transforming the treatment landscape, offering more targeted, convenient, and personalized options that elevate patient outcomes and enhance overall quality of life.
 

• Drugs such as siponimod (Mayzent) and ozanimod (Zeposia) have been engineered to target S1P receptors, which are pivotal in lymphocyte trafficking. By diminishing the count of circulating lymphocytes, these medications mitigate the autoimmune assault on the central nervous system (CNS).
   
• For instance, in March 2019, Novartis received FDA approval for Mayzent (siponimod), an oral medication specifically indicated for treating secondary progressive multiple sclerosis (SPMS) with active disease. The approval benefited patients by offering a more convenient treatment regimen and demonstrated efficacy in reducing disability progression and relapse rates associated with SPMS.
   
• Targeted therapies, notably monoclonal antibodies, have transformed the landscape of multiple sclerosis treatment by focusing on specific immune cells central to the disease. These modern therapies not only excel in reducing relapse rates but also help to slow disease progression when compared to older treatments.
   
• Ongoing clinical trials have shaped the future of multiple sclerosis treatment. Trials for drugs such as ponesimod, Zeposia, and Ocrevus are yielding crucial data on their long-term safety and efficacy, which has helped refine treatment protocols and understand the benefits of these therapies.
   
• Additionally, progress in genomics and biomarker research is enabling a shift towards personalized medicine, where treatments can be tailored based on individual genetic profiles. By identifying specific genetic markers associated with multiple sclerosis, healthcare providers can better match therapies to patients, enhancing treatment efficacy and minimizing adverse effects, thereby propelling market growth.
   

Multiple Sclerosis Therapeutic Market Analysis

Based on drug class, the market is divided into immunosuppressants, immunostimulants, immunomodulators, corticosteroids, and other drug classes. The immunomodulators segment of the market is forecasted to reach USD 23.6 billion by 2032.
 

• Immunomodulators, such as interferon beta and glatiramer acetate, help reduce the frequency and severity of multiple sclerosis relapses by modulating the immune response, leading to fewer episodes of neurological deterioration and better overall disease management.
   
• By altering the immune system’s activity, these treatments can also slow the progression of MS, which is crucial in preventing the accumulation of disability over time and improving long-term patient outcomes.
   
• Furthermore, immunomodulators are effective across various forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), making them versatile treatment options suitable for a wide range of patients.
   
• Collectively, these advantages underscore the pivotal role of immunomodulators in the comprehensive management of multiple sclerosis, offering significant benefits in both early and advanced stages of the disease.

Based on route of administration, the multiple sclerosis therapeutic market is bifurcated into oral and injectables. Further, injectables segment is classified into intramuscular, subcutaneous, and intravenous. The oral segment accounted for USD 14.9 billion in 2023.
 

• Oral medications are easier to administer compared to injectable therapies, improving patient compliance and convenience. They allow patients to take their medication at home without the need for medical supervision, thereby enhancing their quality of life.
   
• The convenience of oral administration often leads to better adherence to the treatment regimen, which is crucial in chronic conditions like multiple sclerosis, where consistent medication use is necessary to manage symptoms and slow disease progression.
   
• Additionally, some oral MS therapies, such as fingolimod, teriflunomide, and dimethyl fumarate, offer novel mechanisms of action that can target different aspects of the immune response, providing additional treatment options tailored to the specific needs of individual patients. This combination of ease of use, improved adherence, and targeted treatment makes oral therapies a valuable option in multiple sclerosis management, thus escalating market growth.
   

Based on distribution channel, the multiple sclerosis therapeutic market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment accounted for USD 13.6 billion in 2023.
 

• Hospital pharmacies specialize in administering multiple sclerosis medications, including complex treatments such as injectables and biologics, ensuring timely and appropriate patient care.
   
• By collaborating closely with neurologists and other healthcare professionals, these pharmacies can tailor multiple sclerosis treatment plans to individual patient needs, adjusting therapies based on disease progression or side effects.
   
• Additionally, hospital pharmacies have access to the latest multiple sclerosis therapies, including newly approved medications or clinical trial drugs that may not be widely available in retail pharmacies, offering patients cutting-edge treatment options and ensuring they receive the most advanced care possible.

The multiple sclerosis therapeutic market in the U.S. projected to reach USD 13.3 billion by 2032.
 

• The high prevalence of multiple sclerosis is a key factor driving growth in the market. According to data from the National Multiple Sclerosis Society, nearly 1 million people in the U.S. were diagnosed with multiple sclerosis in 2019, driving the demand for advanced therapies and spurring continued innovation and growth in the market.
   
• Additionally, the U.S. boasts a highly developed healthcare system with state-of-the-art facilities and specialized centers for multiple sclerosis treatment, providing patients with access to top-tier medical care and innovative therapies.
   

The multiple sclerosis therapeutic market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK has a supportive regulatory framework that facilitates the development and approval of new MS therapies. The Medicines and Healthcare products Regulatory Agency (MHRA) works closely with pharmaceutical companies to ensure timely approval processes.
   
• For instance, in July 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a new 920 mg injection formulation of ocrelizumab (Ocrevus) for treating relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults. This approval highlights the MHRA's dedication to expanding advanced treatment options for multiple sclerosis.
   

Japan multiple sclerosis therapeutic market is anticipated to witness lucrative growth between 2024 and 2032.
 

• Japan has a robust R&D infrastructure, with leading research institutions and pharmaceutical companies focusing on neurological disorders, including multiple sclerosis. This environment fosters innovation and the development of new therapies.
   
• Japan is known for its high-quality clinical trials, which often include diverse patient populations, helping to obtain comprehensive data on the efficacy and safety of MS therapies.
   

The multiple sclerosis therapeutic market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia is fostering collaborations between local healthcare providers, research institutions, and international pharmaceutical companies. These partnerships drive innovation and enhance the availability of new multiple sclerosis therapies.
   
• Saudi Arabia is investing heavily in its healthcare sector, including neurology and multiple sclerosis treatments, as part of its Vision 2030 initiative. This investment supports the development and adoption of advanced multiple sclerosis therapies.
   

Multiple Sclerosis Therapeutic Market Share

The multiple sclerosis therapeutic industry is marked by intense competition, with both major global companies and smaller to medium-sized firms competing for market leadership. A key aspect of market strategy involves the regular introduction of innovative therapies leveraging diverse technologies. Leading industry players significantly drive innovation through substantial investments in research and development. Additionally, strategic partnerships, acquisitions, and mergers are essential for consolidating market positions and expanding international reach.
 

Multiple Sclerosis Therapeutic Market Companies

Some of the eminent market participants operating in the multiple sclerosis therapeutic industry include:

• Abbvie Inc.
• Amgen Inc.
• Acorda Therapeutics, Inc.
• Biogen Inc.
• Bayer AG
• Bristol-Myers Squibb Company.
• F. Hoffman-La Roche Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceuticals Company Limited.
• Pfizer Inc.
• Sanofi
• Viatris Inc.
   

Multiple Sclerosis Therapeutic Industry News:

• In February 2024, F. Hoffmann La-Roche Ltd announced the launch of its breakthrough drug, Ocrevus (Ocrelizumab), for treating multiple sclerosis (MS), expanding its neurology portfolio to address the unmet needs of patients in India. This launch reinforced Roche's commitment to improving neurological care in the region.
   
• In May 2022, Biogen Inc. and MedRhythms entered into an agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for treating gait deficits in multiple sclerosis (MS). This collaboration aimed to expand Biogen’s portfolio in MS treatments, potentially offering a novel therapeutic option and strengthening its position in the health space.
   

The multiple sclerosis therapeutic market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Immunosuppressants
• Immunostimulants
• Immunomodulators
• Corticosteroids
• Other drug classes

Market, By Route of Administration

• Oral
• Injectables
  • Intramuscular
  • Subcutaneous
  • Intravenous

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa